MedTrace Logo

Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)

NCT01723579 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-02-16

No results posted yet for this study

Summary

This study will investigate the efficacy and safety of the monophasic

combined oral contraceptive (COC) containing 2.5 mg NOMAC and 1.5 mg E2 in

healthy fertile Indian women.

Conditions

  • Contraception

Interventions

DRUG

Nomegestrol acetate (NOMAC)

Oral tablet with daily release of 2.5 mg

DRUG

Estradiol (E2)

Daily release of 1.5 mg

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-05-31
Completion
2015-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01723579 on ClinicalTrials.gov